前收市價 | 25.20 |
開市 | 無 |
買盤 | 0.00 |
賣出價 | 0.00 |
拍板 | 30.00 |
到期日 | 2024-05-17 |
今日波幅 | 25.20 - 25.20 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 2 |
Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.
Legend Biotech (LEGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.